Charles River Laboratories International Inc (NYSE:CRL)
$ 219 -2.48 (-1.12%) Market Cap: 11.28 Bil Enterprise Value: 14.03 Bil PE Ratio: 25.70 PB Ratio: 3.10 GF Score: 96/100

Charles River Laboratories International Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 02:00PM GMT
Release Date Price: $129.68 (-0.05%)
Rivka Regina Goldwasser
Morgan Stanley, Research Division - MD

Good morning, everybody. It is my pleasure to introduce our next guest for the day.

To my left is Jim Foster, CEO of Charles River. I think you all know Charles River is a contract research organization and really a market leader in the preclinical segment.

And Jim, when we think about your business, you have a very broad scope of portfolio: Toxicology, animal model, discovery. And you've -- in a great position and have been to really benefit from the increased biopharma spend. So with that in mind, you can take a few minutes just to help frame the conversation for us and just kind of like walk us through what are you seeing in the overall market?

James C. Foster
Charles River Laboratories International, Inc. - Chairman, CEO & President

Yes. I would say that biotech has been a principal driver of our growth for probably 5 or 6 years now. And I don't really know when the crossover was, but we were always the supplier to pharma. And I'd say 8 or 9 years ago, biotech sort of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot